Evidence map›Paper›PMID 32376693›Full record

ArticleThe Journal of biological chemistry2020

The transcription factor GLI1 cooperates with the chromatin remodeler SMARCA2 to regulate chromatin accessibility at distal DNA regulatory elements.

Stephanie L Safgren, Rachel L O Olson, Anne M Vrabel, Luciana L Almada, David L Marks, Nelmary Hernandez-Alvarado, Alexandre Gaspar-Maia, Martin E Fernandez-Zapico

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Stephanie L SafgrenSchulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA.
Rachel L O OlsonSchulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA.
Anne M VrabelSchulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA.
Luciana L AlmadaSchulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA.
David L MarksSchulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA.
Nelmary Hernandez-AlvaradoSchulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA.
Alexandre Gaspar-MaiaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Martin E Fernandez-ZapicoSchulze Center for Novel Therapeutics, Division of Oncology Research, Schulze Center for Novel Therapeutics, Rochester, Minnesota, USA. Electronic address: fernandez-zapico.martin@mayo.edu.
Novel (United States) · USMayo Clinic · US

Funding

Mechanism of Pancreatic CarcinogenesisR01CA136526 · NCI · MAYO CLINIC ROCHESTER · PI FERNANDEZ-ZAPICO, MARTIN ERNESTO · 2009 to 2019
$3.0M
NCI NIH HHS R01 CA136526
6 · The paper itself

Abstract

The transcription factor GLI1 (GLI family zinc finger 1) plays a key role in the development and progression of multiple malignancies. To date, regulation of transcriptional activity at target gene promoters is the only molecular event known to underlie the oncogenic function of GLI1. Here, we provide evidence that GLI1 controls chromatin accessibility at distal regulatory regions by modulating the recruitment of SMARCA2 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 2) to these elements. We demonstrate that SMARCA2 endogenously interacts with GLI1 and enhances its transcriptional activity. Mapping experiments indicated that the C-terminal transcriptional activation domain of GLI1 and SMARCA2's central domains, including its ATPase motif, are required for this interaction. Interestingly, similar to SMARCA2, GLI1 overexpression increased chromatin accessibility, as indicated by results of the micrococcal nuclease assay. Further, results of assays for transposase-accessible chromatin with sequencing (ATAC-seq) after GLI1 knockdown supported these findings, revealing that GLI1 regulates chromatin accessibility at several regions distal to gene promoters. Integrated RNA-seq and ATAC-seq data analyses identified a subset of differentially expressed genes located in

Indexed as

Regulatory Elements, TranscriptionalTranscription Initiation SiteCell Line, TumorChromatinChromatin Assembly and DisassemblyDNAHEK293 CellsHumansProtein DomainsProtein Interaction MapsTranscriptional ActivationTranscription FactorsZinc Finger Protein GLI1ChromatinDNAGLI1 protein, humanSMARCA2 protein, humanTranscription FactorsZinc Finger Protein GLI1actin dependent regulator of chromatinATAC-seqcancercancer cellschromatinchromatin remodelingenhancerepigenetic regulationgene transcriptionGLI family zinc finger 1 (GLI1)matrix associatedmember 2 (SMARCA2)subfamily ASWI/SNF relatedtranscription enhancertranscriptomics

Identifiers

PMID32376693
PMCPMC7324497
OpenAlexW3022676438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.